Health Atlas
Menu
Evidence-led reference
What does this actually mean?Explanation 39

Compounded, generic, brand-name: what is the medicine difference?

What should you check before buying a custom-made or online medicine?

11 sources · Latest source check 2026-10-20 UTC
On this page

Medicine names can conceal important differences in approval, manufacturing and substitution. This guide explains selected US regulatory categories and checks a patient can discuss with a pharmacist.[7]

What does this actually mean?

The meaning

Brand-name, generic, biosimilar and compounded describe different medicine pathways. They are not four quality grades on a shop shelf. In the United States, an approved generic has undergone FDA review against a reference drug. A compounded preparation is made or altered to meet a particular medical need and is not individually FDA approved.[1]

The familiar example

Someone who cannot swallow a tablet might need a liquid preparation; someone allergic to a dye might need a formulation without it. Such needs help explain why compounding exists. That is different from treating any cheaper vial advertised with the same ingredient name as an approved generic. The preparation and the regulatory pathway both matter.[1]

What generic really means

Generic approval requires more than matching the ingredient printed on a label. FDA reviews equivalence, manufacturing and stability. Some inactive ingredients can differ. A change in color or appearance therefore does not by itself show that a generic is weaker or that its active ingredient is different.[2][3]

Where biosimilars fit

Biologics are complex medicines made using living sources. A biosimilar is highly similar to an approved reference biologic with no clinically meaningful difference in safety or effectiveness. It follows a different pathway from a conventional generic. “Interchangeable” has an additional US substitution meaning; it does not mean ordinary biosimilars are inferior.[4]

What a facility claim leaves out

“FDA registered” does not mean that each compounded medicine has been approved. The outsourcing-facility list reports registration and inspection-related information, including facilities not yet inspected. Registration status, a pharmacist’s license, approval of the finished product and suitability for the person taking it answer different questions. A polished telehealth brand cannot replace those checks.[9]

What to check before ordering

Ask who prescribes, who actually prepares or dispenses the medicine, what exact formulation is supplied and why an approved product cannot meet the medical need. Check the pharmacy’s state license, prescription requirement, US address and access to a pharmacist. Request clear strength, storage and use instructions; do not infer a dose from another company’s vial.[10]

The prescribed amount, concentration and syringe marks must fit together

Milligrams describe drug amount; milliliters describe liquid volume. Concentration connects the amount to a volume of liquid. In its 2024 compounded-semaglutide alert, the US Food and Drug Administration described errors involving different concentrations, vial-and-syringe use and confusion between milligrams, milliliters and markings called units. An old syringe instruction cannot automatically be transferred to a new vial.[11]

Evidence & uncertainty

Approval is product specific; pharmacy licensure and facility registration are separate checks. This is a dated educational comparison, not advice to start, substitute or stop a prescription.[9]

Selected-source overview · Independent review pending

Published questions

Is a compounded medicine just another generic?

Selected-source overview · Independent review pending. Read the evidence context.

No. An FDA-approved generic has passed an approval pathway tied to a reference product. A compounded preparation has not received that product approval. Compounding can address a legitimate medical need, but the word generic should not be used to imply that the compounded product has been approved.[1]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Does interchangeable mean a biosimilar works better?

Selected-source overview · Independent review pending. Read the evidence context.

No. In the United States, interchangeability concerns additional requirements for pharmacy-level substitution, subject to state law. FDA-approved biosimilars and interchangeable biosimilars are both expected to have no clinically meaningful safety or effectiveness difference from their reference product. It is a substitution designation, not a superior-effectiveness badge.[4]

Evidence behind this answer
  • Biosimilars Basics for Patients

    agency explanation · Date not stated
    Selected official page passages · Biologic versus biosimilar; interchangeability and state substitution law

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Does a registered outsourcing facility sell FDA-approved compounded medicines?

Selected-source overview · Independent review pending. Read the evidence context.

Registration identifies an outsourcing facility and brings specific oversight requirements. It does not grant approval to its compounded products. FDA’s list includes inspection and recall information; a listing alone is not a conclusion that every product or batch meets all applicable requirements.[9]

Evidence behind this answer
  • Registered Outsourcing Facilities

    agency explanation · Date not stated
    Selected official page passages · Registration table and footnotes; inspection and recall information

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Does a local pharmacy being out of stock automatically permit a compounded copy?

Selected-source overview · Independent review pending. Read the evidence context.

A local stock problem is not the same as a drug appearing on FDA’s national shortage list. Federal compounding conditions differ by pathway. FDA’s April 1, 2026 update describes restrictions and patient-specific exceptions; it is not a blanket authorization to make copies whenever a patient cannot find stock.[6]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Where can I check an approved generic or biologic counterpart?

Selected-source overview · Independent review pending. Read the evidence context.

FDA’s Orange Book helps identify approved drug products and therapeutic-equivalence information. The Purple Book identifies licensed biologics, including biosimilar and interchangeable products. Use the exact ingredient and product details, and ask a pharmacist to interpret the result rather than relying on a seller’s generic label.[7][8]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

What can go wrong if a compounded product is poorly made?

Selected-source overview · Independent review pending. Read the evidence context.

FDA describes risks such as contamination, excessive or insufficient active ingredient and inadequate directions. Those problems can have serious consequences. Their possibility does not make every compounded prescription illegitimate; it explains why the medical need, actual preparer, quality controls and clear instructions matter.[5]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

What should you check before buying a custom-made or online medicine?

Selected-source overview · Independent review pending. Read the evidence context.

Identify the actual pharmacy and formulation, and discuss why an approved product cannot meet the medical need. Verify pharmacy licensure, a valid prescription requirement and access to a pharmacist. Request clear concentration, storage and use instructions. A clinic’s branding or a facility registration alone does not establish approval of the preparation.[10][5]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Equivalence is an evidence requirement, not a price claim

For a generic, FDA checks whether the active ingredient is the same, whether the formulation and release characteristics are appropriate, and whether the drug behaves sufficiently similarly in the body. Manufacturing and stability information also undergo review. A lower price does not mean that a generic is permitted to deliver less active treatment. Conversely, sharing an ingredient name is insufficient to show equivalence between two products.[2]

The Orange Book links approval information with therapeutic-equivalence evaluations. That is a more useful verification route than a clinic’s own branding. The relevant match includes the particular form, strength and route, not simply a familiar molecule name. Ask a pharmacist to resolve uncertain matches.[7]

Compounding has a medical purpose and specific conditions

Under US federal law, the 503A pathway generally involves patient-specific prescribing, while 503B outsourcing facilities operate under a different set of conditions. They are not interchangeable labels for the same business model. State pharmacy oversight and FDA oversight have different roles. A prescription alone does not turn an unapproved preparation into an approved one.[6]

In its April 1, 2026 update, FDA explained that tirzepatide and semaglutide were neither on the national shortage list nor the 503B bulks list. Copy restrictions and documented significant-difference exceptions require their own assessment. This dated example should be rechecked before interpreting a current offer; it does not imply that all compounding is prohibited.[6]

A practical verification conversation

Separate the clinic collecting payment from the pharmacy supplying the medicine. An online service can be legitimate, but a website’s professional appearance is not verification. FDA recommends checking the pharmacy’s license and access to a pharmacist, and whether it requires a valid prescription. Identify the actual supplier before sharing medical or payment information.[10]

If a medicine is compounded, ask for the precise concentration and directions rather than assuming another product’s syringe markings apply. Ask how storage and transport protect quality and whom to contact about an unexpected problem. These questions address quality uncertainty; they do not establish a personal conversion schedule or remove the need for clinical follow-up.[5]

References

  1. Compounding and the FDA: Questions and Answers

    Agency explanation

    FDA · Content/publication date: not stated
    Accessed: 2026-10-15 UTC · Selected official page passages
    Cited sections: Patient-specific need; lack of approval; oversight distinctions

  2. Generic Drug Facts

    Agency explanation

    FDA · Content/publication date: not stated
    Accessed: 2026-10-15 UTC · Selected official page passages
    Cited sections: Equivalence, manufacturing, stability and price

  3. Generic Drugs: Specific Labeling Resources

    Agency explanation

    FDA · Content/publication date: not stated
    Accessed: 2026-10-15 UTC · Selected official page passages
    Cited sections: Permissible labeling differences, including inactive ingredients

  4. Biosimilars Basics for Patients

    Agency explanation

    FDA · Content/publication date: not stated
    Accessed: 2026-10-15 UTC · Selected official page passages
    Cited sections: Biologic versus biosimilar; interchangeability and state substitution law

  5. Understanding the Risks of Compounded Drugs

    Agency explanation

    FDA · Content/publication date: not stated
    Accessed: 2026-10-15 UTC · Selected official page passages
    Cited sections: Contamination, strength and label risks; lawful medical need

  6. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize

    Agency explanation

    FDA · Content/publication date: 2026
    Accessed: 2026-10-15 UTC · Selected official page passages
    Cited sections: April 1, 2026 policy update; 503A/503B conditions; shortage distinction

    Dated US policy snapshot; not a legal opinion on an individual prescription.

  7. Approved Drug Products with Therapeutic Equivalence Evaluations: Orange Book

    Agency explanation

    FDA · Content/publication date: not stated
    Accessed: 2026-10-15 UTC · Selected official page passages
    Cited sections: Background; ingredient, form, route and applicant search

  8. Purple Book Search

    Agency explanation

    FDA · Content/publication date: not stated
    Accessed: 2026-10-15 UTC · Selected official page passages
    Cited sections: Database scope and product-name search

  9. Registered Outsourcing Facilities

    Agency explanation

    FDA · Content/publication date: not stated
    Accessed: 2026-10-15 UTC · Selected official page passages
    Cited sections: Registration table and footnotes; inspection and recall information

  10. BeSafeRx: Frequently Asked Questions

    Agency explanation

    FDA · Content/publication date: not stated
    Accessed: 2026-10-15 UTC · Selected official page passages
    Cited sections: Questions 3–4: prescription, license, address and pharmacist checks

  11. FDA alert on dosing errors associated with compounded injectable semaglutide

    Regulatory safety alert

    US Food and Drug Administration · Content/publication date: 2024
    Accessed: 2026-10-20 UTC · original regulatory safety alert read. Complete main alert, measurement and concentration sections, reports and boundaries. No independent full evidence appraisal or qualified review completed.
    Cited sections: Complete main alert, measurement and concentration sections, reports and boundaries.

    Historical measurement-error alert; no individual dose conversion.

Scope & review

Population
General adult readers comparing medicine terminology
Exposure or intervention
Approved generic and biosimilar pathways versus compounded preparations
Comparison
US FDA approval, substitution and facility-oversight categories
Outcomes
Understanding evidence requirements and verifying a medicine offer
Timeframe
Selected official sources checked October 15, 2026; policy example dated April 1, 2026
Jurisdiction
United States; substitution also depends on state law; other countries differ

Selected primary-source educational explanation; not an exhaustive search, a formal evidence grade or qualified medical review.

Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.

Revision history
  • 2026-10-15 UTC: Added a definition-first plain-English guide from selected original guidance and publications; qualified medical review remains pending.
  • 2026-10-15 UTC: Added the plain-English series explanation with definitions, distinctions, practical questions and selected primary sources; qualified review remains pending.
  • 2026-10-20 UTC: Added bounded depth26 explanation after complete target and relevant neighboring-body audit; old section, FAQ and source objects retained exactly. Original-source access and cumulative current/pending work accounting recorded; qualified review remains pending.

What this article still leaves open

  • Country-specific substitution and compounding rules beyond the selected US examples
  • Comparative outcomes and batch-quality evidence for individual compounded preparations
  • Subsequent FDA policy, litigation or shortage-list changes
Suggest a correction

Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.

More in the plain-English series

Keep making sense of it.

Explore Prevention & care explanations See every explanation

Explore the topic map

Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.